Outcomes After Biochemical or Clinical Progression in Patients With Multiple Myeloma

All evaluable patients achieved minimal residual disease negativity following teclistamab-based treatment in the phase 3 MajesTEC-4/EMN30 trial.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Daratumumab plus VRd showed a deepened MRD and PFS rate for patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.